Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Kaufen / Verkaufen

Top-Partner CFD-Broker

Plus500
  • Keine Kommissionen, enge Spreads
  • Hebel- und Long/Short-Trading, fortgeschrittene Analysetools, kostenlose Echtzeitkurse etc.
  • CFD-Trading auf Aktien, Indizes, Krypto, Rohstoffe und Devisen
Direkt zu Plus500 CFD service. Ihr Kapital unterliegt einem Risiko.

Premium-Partner

IG Bank
  • Ein weltweit führender CFD-Anbieter*, FINMA-reguliert
  • Über 17'000 Märkte: Indizes, Devisen, Rohstoffe, Aktien, Kryptowährungen, Optionen und mehr
  • Erweiterte Handelszeiten und Wochenendhandel
  • Schweizer Kundenserviceteam, mit Büros in Genf und Zürich
*Die IG Gruppe ist grösster Anbieter nach Umsatz (veröffentlichter Geschäftsbericht 2022)
Direkt zur IG Bank Verluste können Einlagen übersteigen.
Saxo Bank
  • Lizenzierte Schweizer Bank (FINMA)
  • Keine Depotgebühren bei aktivierter Wertpapierleihe
  • Aktien, ETFs, Optionen, FX, CFDs, Futures, Rohstoffe, Bonds, Mutual Funds - auf einer Plattform
  • Gratis Expertenanalysen und Trading-Signale
  • Saxo Deal: Rückerstattung der Courtagen bis CHF 200 während 90 Tagen
Direkt zur Saxo Bank
Werbung
<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
08.11.2024 10:45:06

EQS-News: SEBASTIAN BRAUN WINS EY ENTREPRENEUR OF THE YEAR

EQS-News: CHEPLAPHARM AG / Key word(s): Miscellaneous
SEBASTIAN BRAUN WINS EY ENTREPRENEUR OF THE YEAR

08.11.2024 / 10:45 CET/CEST
The issuer is solely responsible for the content of this announcement.


SEBASTIAN BRAUN WINS EY ENTREPRENEUR OF THE YEAR

Greifswald, 08. November 2024

  • Sebastian Braun wins prestigious entrepreneur award in the ‘family business’ category
  • First award winner from the eastern German states since 2014
  • The EY Entrepreneur of the Year Award is presented in 60 countries

 

Sebastian Braun, Chairman of the Supervisory Board, main owner together with his sister Dr Bianca Juha and former CEO of the CHEPLAPHARM Group for many years, is EY Entrepreneur of the Year. He was honoured yesterday evening at a gala ceremony at Motorwerk Berlin in the ‘family business’ category. The EY Entrepreneur of the Year is awarded annually in 60 countries and is considered one of the most prestigious business awards worldwide.

 

Over the past 20 years, Sebastian Braun has transformed CHEPLAPHARM from a small company with an annual turnover of 600,000 euros into a global market leader in the acquisition of established off-patent branded medicines with an annual turnover of 1.5 billion euros (FY/2023). The group has a global network of 125 contract manufacturers and 100 distribution partners, ensuring a continuous supply of reliable medicines to patients and maintaining global drug diversity. Today, CHEPLAPHARM employs around 750 people at locations in Germany, France, Japan, Russia and Switzerland.


For Sebastian Braun, good entrepreneurship is one thing above all: ‘Success is no coincidence - it's always a combination of preparation and opportunity. If you want to be successful, you have to constantly educate yourself in your business field, know your stuff - and then act boldly when opportunities arise.’ A maxim that probably also convinced the jury of experts, who selected the winners based on four key criteria: ‘Entrepreneurship’, which represents entrepreneurial thinking and action, ‘Purpose’, which reflects the company's purpose and vision, ‘Growth’, which stands for growth and future potential, and ‘Impact’, which includes impact and corporate responsibility.

‘Winning this prestigious business award fills me with great pride and I accept it on behalf of my fantastic team. It is the result and at the same time proof of the work we have done together in recent years and a success story that would not have been possible without the CHEPLAPHARM workforce,’ says Sebastian Braun, delighted with the award. ‘As the first award winner from Eastern Germany in ten years, I am particularly pleased to have brought the prize home - for our employees, for our company and for the state of Mecklenburg-Vorpommern.’

 

Sebastian Braun represents Germany at the EY World Entrepreneur Of The Year 2025

It took ten years before Sebastian Braun to be honoured again as an entrepreneur from eastern Germany (excluding Berlin). In 2014, NOMOS Glashütte/SA Roland Schwertner KG was the last winner from eastern Germany. But that's not all: This year, Sebastian Braun will receive another honour: he will represent Germany at the EY World Entrepreneur Of The Year in Monaco in 2025.

 

About the ‘EY Entrepreneur Of The Year’ competition

In addition to Sebastian Braun in the ‘family business’ category, three other entrepreneurial personalities were honoured this year in the categories sustainability, innovation and young company. There were five finalists to choose from in each category. The ‘Entrepreneur Of The Year’ programme was launched by EY in the USA in 1986. Since then, the competition has established itself in around 60 countries and is one of the world's most prestigious entrepreneur awards. The competition is being organised in Germany for the 28th time this year and is supported by well-known companies and media. These include LGT, the Frankfurter Allgemeine Zeitung and manager magazin. In addition to honouring successful business personalities, EY also promotes the next generation of entrepreneurs with its ‘EY NextGen Academy’ programme. For further information, please visit the following website: http://www.de.ey.com/eoy

 

About CHEPLAPHARM

CHEPLAPHARM is a family-owned company with headquarters in Greifswald. For over 20 years, the company has been very successful in taking over well-known and well-established medicines from the research-based pharmaceutical industry and transferring them to an existing global network of partners for production and distribution. In this way, CHEPLAPHARM ensures the continuous supply of these medicines to patients worldwide. In addition to its headquarters in Greifswald, CHEPLAPHARM operates further sites in France, Japan, Russia and Switzerland. The company employs around 750 people worldwide.

 

Please refer to www.cheplapharm.com for additional information.

 

Press office:

CHEPLAPHARM ǀ Ziegelhof 24 ǀ 17489 Greifswald ǀ press(at)cheplapharm.com

 

 



08.11.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Cheplapharm AG
Ziegelhof 24
17489 Greifswald
Germany
Phone: 03834 3914 O
E-mail: info@cheplapharm.com
Internet: www.cheplapharm.com
ISIN: DE000CHP2222
WKN: CHP222
EQS News ID: 2026065

Notierung vorgesehen
 
End of News EQS News Service

2026065  08.11.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=2026065&application_name=news&site_id=finanzen_net~~~069d1026-6a45-454f-953c-2a2c4451f1d6

Analysen zu CHEPLAPHARM

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

3 Knaller-Aktien im BX Musterportfolio📈: Fiserv Inc., Cintas & Blackstone mit François Bloch

Im BX Morningcall werden folgende Aktien analysiert und erklärt:
✅ Fiserv Inc.
✅ Cintas
✅ Blackstone

👉🏽 https://bxplus.ch/bx-musterportfolio/

3 Knaller-Aktien im BX Musterportfolio📈: Fiserv Inc., Cintas & Blackstone mit François Bloch

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’200.00 19.38
Short 12’426.58 13.76 UBS07U
Short 12’872.76 9.00 UMBS6U
SMI-Kurs: 11’709.80 28.11.2024 17:31:09
Long 11’207.11 19.50 S5TMZU
Long 10’925.55 13.29 SSQMQU
Long 10’504.40 9.00 5SSMZU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}

Nachrichten

  • Nachrichten zu Aktien
  • Alle Nachrichten